EGFR and non-small cell lung carcinoma: EGFR is overexpressed in a majority of NSCLC cases; however, two available EGFR TKIs, erlotinib and gefitinib, have yielded poor responses in NSCLC patients with a history of smoking compared to patients who have never smoked [111].